GE HealthCare (GEHC) President and CEO Peter Arduini discusses the company's $1 billion imaging deal with Sutter Health and the future of AI in the health-care industry. He speaks with Katie Greifeld at the JPMorgan Healthcare Conference in San Francisco.
Presently, Peter J. Arduini occupies the position of President, Chief Executive Officer & Director at Integra LifeSciences Holdings Corp., President for Ascension Orthopedics, Inc. (a subsidiary of Integra LifeSciences Holdings Corp.) and President of Ascención Orthopedics, Inc. He is also on the board of 5 other companies.
In the past Mr. Arduini held the position of Vice President & President-Medication Delivery at Baxter International, Inc. President & Vice President at Medication Delivery Devices, Inc. and President-Medical Delivery & Vice President at Baxter Healthcare Corp. (both are subsidiaries of Baxter International, Inc.), Global General Manager-CT Scan at General Electric Healthcare Technologies, Inc. and General Manager-Global Imaging Business at GE Healthcare, Inc.
Peter J. Arduini received an undergraduate degree from Susquehanna University and a graduate degree from Kellogg School of Management.
GE HealthCare Technologies Inc. is a medical technology, pharmaceutical diagnostics, and digital solutions company. The Company provides integrated solutions, services, and data analytics. Its segments include Imaging, Ultrasound, Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). Its Imaging segment offers a comprehensive portfolio of scanning devices, clinical applications, service capabilities, and digital solutions. Its Ultrasound segment includes ultrasound medical devices and solutions with a portfolio of continuum of care, including screening, diagnosis, treatment, and monitoring of certain diseases. The segment also includes the clinical artificial intelligence (AI) software business. Its PCS segment portfolio consists of patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, maternal infant care, and consumables and services. Its PDx segment consists of two business lines: contrast media and molecular imaging.
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
